Year All20262025202420232022 Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC May 21, 2026 Read More Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) May 13, 2026 Read More Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update May 11, 2026 Read More Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET May 04, 2026 Read More Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Apr 03, 2026 Read More Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Mar 30, 2026 Read More Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET Mar 23, 2026 Read More Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Mar 04, 2026 Read More Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Feb 26, 2026 Read More Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants Feb 24, 2026 Read More Bicara Therapeutics Announces Proposed Public Offering of Common Stock Feb 24, 2026 Read More Bicara Therapeutics to Participate in Upcoming Investor Conferences Feb 23, 2026 Read More Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen Feb 19, 2026 Read More Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Feb 05, 2026 Read More Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook Jan 12, 2026 Read More
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC May 21, 2026 Read More
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) May 13, 2026 Read More
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update May 11, 2026 Read More
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET May 04, 2026 Read More
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Apr 03, 2026 Read More
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Mar 30, 2026 Read More
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET Mar 23, 2026 Read More
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Mar 04, 2026 Read More
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Feb 26, 2026 Read More
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants Feb 24, 2026 Read More
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen Feb 19, 2026 Read More
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Feb 05, 2026 Read More
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook Jan 12, 2026 Read More
